CXCL9 and macrophage activation syndrome: Rodriguez-Smith et al. reported that eight (42%) of 19 patients with MIS-C who met MAS criteria (also based on 2016 MAS classification) had significantly higher CXCL9 concentration than patients with MIS-C without MAS.